Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Cherrypinkon Feb 18, 2021 9:03am

129 Views

Post# 32593987

CB Market

Sponsored Post:

These other companies appear to be even more bullish and believes that sales might reach approximately $16 billion by 2025. This is an entertaining scenario to picture out what's on your mind! Check here.

CB* appears to be one of the most searched health trends, even outnumbering searches for veganism, exercise, and even vaccines.

These other companies appear to be finding a niche in the functional foods sector- a sector that is projected to reach about $34.3 billion by 2024 at a CAGR of approximately 8.94% between 2019 and 2024. Check disclaimer on landing page and in my profile.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing